 Hui Zhang
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 20 | 2024 | 1894 | 2.740 |
Why?
| | Fibroblasts | 9 | 2024 | 953 | 1.370 |
Why?
| | MicroRNAs | 4 | 2021 | 679 | 0.960 |
Why?
| | Polypyrimidine Tract-Binding Protein | 3 | 2017 | 17 | 0.740 |
Why?
| | Heterogeneous-Nuclear Ribonucleoproteins | 2 | 2017 | 18 | 0.710 |
Why?
| | Pyruvate Kinase | 2 | 2017 | 26 | 0.700 |
Why?
| | Immunotoxins | 3 | 2025 | 54 | 0.650 |
Why?
| | Disease Susceptibility | 1 | 2021 | 334 | 0.620 |
Why?
| | RNA-Binding Proteins | 1 | 2020 | 387 | 0.530 |
Why?
| | Hypoxia | 8 | 2024 | 1084 | 0.470 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2023 | 209 | 0.460 |
Why?
| | Diphtheria Toxin | 3 | 2025 | 65 | 0.460 |
Why?
| | Pulmonary Artery | 6 | 2024 | 1097 | 0.450 |
Why?
| | Gene Expression Regulation | 4 | 2021 | 2542 | 0.430 |
Why?
| | Vascular Remodeling | 4 | 2023 | 192 | 0.390 |
Why?
| | Animals | 25 | 2025 | 35391 | 0.350 |
Why?
| | Cellular Reprogramming | 3 | 2021 | 95 | 0.340 |
Why?
| | Cell Proliferation | 6 | 2023 | 2373 | 0.330 |
Why?
| | Familial Primary Pulmonary Hypertension | 3 | 2017 | 199 | 0.280 |
Why?
| | Interleukin-2 | 3 | 2024 | 437 | 0.280 |
Why?
| | Macrophages | 6 | 2022 | 1488 | 0.280 |
Why?
| | Cattle | 5 | 2023 | 977 | 0.240 |
Why?
| | Glycolysis | 5 | 2017 | 315 | 0.240 |
Why?
| | CD47 Antigen | 1 | 2025 | 28 | 0.230 |
Why?
| | Lignans | 1 | 2024 | 13 | 0.230 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 26 | 0.230 |
Why?
| | Mice | 14 | 2025 | 16961 | 0.230 |
Why?
| | Signal Transduction | 5 | 2024 | 4931 | 0.220 |
Why?
| | Biphenyl Compounds | 1 | 2024 | 60 | 0.220 |
Why?
| | NAD | 1 | 2024 | 75 | 0.220 |
Why?
| | Sirtuin 3 | 1 | 2024 | 58 | 0.220 |
Why?
| | Sezary Syndrome | 1 | 2023 | 44 | 0.210 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 61 | 0.210 |
Why?
| | Sildenafil Citrate | 1 | 2023 | 59 | 0.200 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2023 | 43 | 0.200 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 2046 | 0.200 |
Why?
| | Glucosephosphate Dehydrogenase | 2 | 2020 | 56 | 0.200 |
Why?
| | Cells, Cultured | 5 | 2021 | 4084 | 0.190 |
Why?
| | Purines | 1 | 2023 | 172 | 0.190 |
Why?
| | Macrophages, Alveolar | 2 | 2024 | 389 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 274 | 0.180 |
Why?
| | Histone Deacetylases | 2 | 2021 | 212 | 0.180 |
Why?
| | Antagomirs | 2 | 2017 | 12 | 0.180 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2020 | 259 | 0.180 |
Why?
| | Vasodilator Agents | 1 | 2023 | 326 | 0.180 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2021 | 87 | 0.180 |
Why?
| | Transcriptome | 2 | 2024 | 876 | 0.170 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 169 | 0.170 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 83 | 0.170 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2020 | 444 | 0.170 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 231 | 0.170 |
Why?
| | Macrophage Activation | 1 | 2021 | 189 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 129 | 0.160 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2020 | 87 | 0.160 |
Why?
| | Disease Models, Animal | 7 | 2024 | 4078 | 0.160 |
Why?
| | RNA Interference | 2 | 2017 | 450 | 0.150 |
Why?
| | Humans | 18 | 2025 | 129626 | 0.150 |
Why?
| | Mice, SCID | 3 | 2025 | 350 | 0.150 |
Why?
| | Mice, Inbred C57BL | 5 | 2024 | 5455 | 0.150 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 235 | 0.140 |
Why?
| | Naphthoquinones | 1 | 2017 | 19 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 544 | 0.140 |
Why?
| | Rats | 6 | 2024 | 5483 | 0.140 |
Why?
| | Chromatin | 1 | 2021 | 479 | 0.140 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1687 | 0.140 |
Why?
| | Energy Metabolism | 3 | 2017 | 875 | 0.130 |
Why?
| | Complement Activation | 1 | 2020 | 384 | 0.130 |
Why?
| | Transcription, Genetic | 2 | 2021 | 1418 | 0.130 |
Why?
| | Transcriptional Activation | 1 | 2018 | 367 | 0.130 |
Why?
| | Mitochondria | 3 | 2017 | 876 | 0.130 |
Why?
| | Alcohol Oxidoreductases | 1 | 2016 | 60 | 0.130 |
Why?
| | Protein Isoforms | 1 | 2017 | 388 | 0.130 |
Why?
| | Histones | 1 | 2021 | 589 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 217 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2023 | 829 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2020 | 851 | 0.120 |
Why?
| | Interleukin-1beta | 1 | 2017 | 372 | 0.120 |
Why?
| | DNA Methylation | 1 | 2020 | 611 | 0.120 |
Why?
| | Muscle, Skeletal | 1 | 2024 | 1613 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2020 | 2708 | 0.100 |
Why?
| | Phenotype | 5 | 2020 | 3075 | 0.090 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3186 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2025 | 587 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2017 | 903 | 0.090 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2023 | 145 | 0.090 |
Why?
| | Endothelial Cells | 3 | 2023 | 749 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2025 | 808 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2133 | 0.080 |
Why?
| | Biomarkers | 1 | 2021 | 3968 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2016 | 1445 | 0.080 |
Why?
| | Cell Movement | 1 | 2013 | 948 | 0.080 |
Why?
| | Oxidation-Reduction | 3 | 2017 | 1028 | 0.080 |
Why?
| | Lung | 4 | 2024 | 3938 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2395 | 0.070 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1366 | 0.070 |
Why?
| | Superoxides | 2 | 2017 | 201 | 0.060 |
Why?
| | Allyl Compounds | 1 | 2024 | 21 | 0.060 |
Why?
| | Sirtuins | 1 | 2024 | 39 | 0.060 |
Why?
| | Receptors, CCR4 | 1 | 2024 | 21 | 0.060 |
Why?
| | Phenols | 1 | 2024 | 96 | 0.050 |
Why?
| | Swine, Miniature | 1 | 2024 | 81 | 0.050 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 617 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2020 | 2881 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2024 | 273 | 0.050 |
Why?
| | Physical Conditioning, Animal | 1 | 2024 | 229 | 0.050 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 111 | 0.050 |
Why?
| | Swine | 1 | 2024 | 764 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 546 | 0.040 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 70 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2021 | 110 | 0.040 |
Why?
| | Ventricular Remodeling | 1 | 2023 | 255 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 482 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 276 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2021 | 223 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2020 | 12 | 0.040 |
Why?
| | Complement C5 | 1 | 2020 | 78 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2022 | 427 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2022 | 607 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2020 | 161 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 147 | 0.040 |
Why?
| | Complement Factor B | 1 | 2020 | 109 | 0.040 |
Why?
| | Complement Pathway, Alternative | 1 | 2020 | 120 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 627 | 0.040 |
Why?
| | Complement C3 | 1 | 2020 | 209 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2021 | 651 | 0.040 |
Why?
| | Lim Kinases | 1 | 2017 | 5 | 0.040 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2017 | 21 | 0.040 |
Why?
| | Smad5 Protein | 1 | 2017 | 8 | 0.040 |
Why?
| | Smad1 Protein | 1 | 2017 | 18 | 0.040 |
Why?
| | Heart Ventricles | 1 | 2023 | 781 | 0.040 |
Why?
| | Metabolome | 1 | 2021 | 340 | 0.040 |
Why?
| | Male | 5 | 2024 | 63670 | 0.030 |
Why?
| | RNA, Long Noncoding | 1 | 2020 | 179 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2017 | 51 | 0.030 |
Why?
| | Pentose Phosphate Pathway | 1 | 2017 | 51 | 0.030 |
Why?
| | Symporters | 1 | 2017 | 56 | 0.030 |
Why?
| | Up-Regulation | 1 | 2020 | 840 | 0.030 |
Why?
| | Pyruvate Dehydrogenase Complex | 1 | 2016 | 8 | 0.030 |
Why?
| | Isoenzymes | 1 | 2017 | 301 | 0.030 |
Why?
| | Citric Acid Cycle | 1 | 2016 | 54 | 0.030 |
Why?
| | Proteomics | 1 | 2023 | 1055 | 0.030 |
Why?
| | Cell Respiration | 1 | 2016 | 98 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2016 | 39 | 0.030 |
Why?
| | Pyruvic Acid | 1 | 2016 | 52 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 43 | 0.030 |
Why?
| | Paracrine Communication | 1 | 2016 | 61 | 0.030 |
Why?
| | Inflammation | 2 | 2020 | 2750 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2017 | 541 | 0.030 |
Why?
| | Carbon | 1 | 2017 | 204 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2016 | 188 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2017 | 591 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 887 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1465 | 0.030 |
Why?
| | Down-Regulation | 1 | 2016 | 636 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 74 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 62 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2013 | 117 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 117 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2013 | 138 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2013 | 183 | 0.030 |
Why?
| | Female | 4 | 2025 | 68734 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2013 | 442 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 1002 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2018 | 1266 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 3774 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1720 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 2124 | 0.020 |
Why?
| | United States | 1 | 2023 | 13871 | 0.020 |
Why?
| | Adult | 1 | 2013 | 35599 | 0.010 |
Why?
|
|
Zhang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|